Frain Bridget, Castelino Ronald, Bereznicki Luke R
1 Unit for Medication Outcomes Research and Education, Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia.
Clin Appl Thromb Hemost. 2018 Apr;24(3):519-524. doi: 10.1177/1076029616686421. Epub 2017 Jan 10.
Oral anticoagulants are essential drugs for the prevention of thromboembolic events in patients with atrial fibrillation (AF). Anticoagulants are, however, commonly withheld in older people due to the risk and fear of hemorrhage. Although the underutilization of anticoagulants in patients with AF has been demonstrated internationally, few studies have been conducted among aged care residents. The aim of this study was to determine the utilization of anticoagulants among people with AF residing in aged care facilities. We performed a non-experimental, retrospective analysis designed to evaluate antithrombotic usage in patients with AF in Australia residing in aged care facilities, using data collected by pharmacists while performing Residential Medication Management Reviews (RMMRs). The utilization of antithrombotic therapy and the appropriateness of therapy were determined based on the CHADS, CHADS-VASc, and HAS-BLED risk stratification schemes in consideration of documented contraindications to treatment. Predictors of anticoagulant use were determined using multivariate logistic regression. A total of 1952 RMMR patients with AF were identified. Only 35.6% of eligible patients (CHADS score ≥2 and no contraindications to anticoagulants) received an anticoagulant. As age increased, the likelihood of receiving an anticoagulant decreased and the likelihood of receiving an antiplatelet or no therapy increased. In patients at high risk of stroke (CHADS score ≥2), utilization of anticoagulants dropped by 19.7% when the HAS-BLED score increased from 2 to 3, suggesting that physicians placed a heavier weighting on bleeding risk rather than stroke risk. Prescribing of anticoagulants was influenced to a greater extent by bleeding risk than it was by the risk of stroke. Further research investigating whether the growing availability of direct oral anticoagulants influences practice in this patient population is needed.
口服抗凝剂是预防心房颤动(AF)患者血栓栓塞事件的重要药物。然而,由于出血风险和对出血的恐惧,老年人通常停用抗凝剂。尽管AF患者抗凝剂使用不足在国际上已得到证实,但针对老年护理机构居民的研究却很少。本研究的目的是确定居住在老年护理机构的AF患者中抗凝剂的使用情况。我们进行了一项非实验性回顾性分析,旨在评估居住在澳大利亚老年护理机构的AF患者的抗血栓药物使用情况,使用药剂师在进行住院药物管理评估(RMMR)时收集的数据。根据CHADS、CHADS-VASc和HAS-BLED风险分层方案,并考虑已记录的治疗禁忌症,确定抗血栓治疗的使用情况和治疗的适当性。使用多变量逻辑回归确定抗凝剂使用的预测因素。共识别出1952例患有AF的RMMR患者。只有35.6%的符合条件的患者(CHADS评分≥2且无抗凝剂使用禁忌症)接受了抗凝剂治疗。随着年龄的增加,接受抗凝剂治疗的可能性降低,接受抗血小板治疗或不接受任何治疗的可能性增加。在中风高危患者(CHADS评分≥2)中,当HAS-BLED评分从2增加到3时,抗凝剂的使用率下降了19.7%,这表明医生更重视出血风险而非中风风险。与中风风险相比,出血风险对抗凝剂处方的影响更大。需要进一步研究调查直接口服抗凝剂可用性的增加是否会影响该患者群体的治疗实践。